Taking the different path

Lpath Inc. thinks its mAbs against sphingosine 1-phosphate will work better in cancer than S1P receptor agonists in development. The company believes the agonists actually cause side effects through their agonist activity, while ultimately exerting their efficacy by overloading the receptors and shutting them down.

Last week, Merck KGaA's Merck Serono S.A. subsidiary took out an option on Lpath's lead compound, Asonep...